Fig. 5: RG4 hinders the efficacy of SARS-CoV-2 infection in vivo.
From: RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection
a Schematic of in vivo experimental plans. 6–8-week-old C57BL/6 J mice were transduced intrathoracic with an AAV coding for human ACE2 (AAV9-hACE2) and infected with VSV-SARS-2-S-luc after 7 days. From one day before the infection, mice were infused with PDS (6 mg/kg body weight) or saline via caudal vein daily. Following measurements were performed on day 8 post infection (n = 6). b Representative H&E staining (top panel) and IHC staining for TMPRSS2 (bottom panel) in paraffin lung sections. Scale bars: 100 μm. c Representative photos of the VSV-SARS-2-S-luc-infected mice. The relative levels of bioluminescence are shown in pseudocolors, with blue and red representing the weakest and strongest photon fluxes, respectively. d Photon emission from each mouse was quantified as radiance (p/s/cm2/sr) post-imaging, using region of interest analysis in living image software. e Levels of Renilla mRNA in the VSV-SARS-2-S-luc-infected mouse lungs. f–h Levels of TMPRSS2 protein in the VSV-SARS-2-S-luc-infected mouse lungs analyzed by ELISA (f) or western blot (g). ImageJ quantification of the TMPRSS2/ACTIN ratio in (g) is shown (h). i A schematic model of RG4 regulation in SARS-CoV-2 infection. Data are shown as mean ± SEM, n = 6. Two-tailed Student’s t test. Source data are provided as a source data file.
